Snowden Capital Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Snowden Capital Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$422K	Buy	+1,583	New	+$370K	0.01%	919

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Snowden Capital Advisors's ASND Position: Q2 2026 in Review

Snowden Capital Advisors opened a new position in Ascendis Pharma A/S (ASND) in Q2 2026: 1,583 shares worth $422K. The stake represents 0.01% of the portfolio and ranks #919 among its holdings.

311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Snowden Capital Advisors held 1,583 shares of Ascendis Pharma A/S worth $422K as of Q2 2026.
Ascendis Pharma A/S was a new Snowden Capital Advisors position in Q2 2026.
Ascendis Pharma A/S made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #919 holding.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.